Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata; Lifecore is a subsidiary) on July 23, 2020. The filing reports the adoption of an Executive Change in Control Severance Plan and the execution of an amended employment agreement for the CEO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and corporate governance changes.
Material Changes
- Adoption of Severance Plan: The Board adopted the "Landec Corporation Executive Change in Control Severance Plan" effective July 23, 2020. This plan covers executives including James Hall (President of Lifecore and VP of Landec) and Brian McLaughlin (CFO).
- CEO Employment Agreement: The Board approved an amended and restated employment agreement for Albert Bolles (President and CEO), effective July 23, 2020, with a term ending July 23, 2023.
Guidance, Outlook, and Management Commentary
The filing details specific severance triggers and benefits but provides no financial guidance or operational outlook. Key terms include:
- Trigger Events: Payments are triggered by termination without "cause" or resignation for "good reason" within two years of a "change in control."
- Severance Benefits (General Executives): Lump sum payment of one year's base salary plus target bonus; pro-rated bonus; up to 12 months of COBRA subsidies; and full accelerated vesting of equity awards.
- Severance Benefits (CEO): One year's base salary plus target bonus paid in installments over 18 months; pro-rated bonus; COBRA subsidies for the maximum permitted period; and full accelerated vesting of equity awards.
- Golden Parachute Reduction: Payments may be reduced if they trigger an excise tax under Section 4999 of the Internal Revenue Code, provided the reduction yields a better net after-tax result for the executive.
Investor Verification Checklist
- Verify the distinction between the registrant (Landec Corporation) and the subsidiary mentioned (Lifecore Biomedical, Inc.).
- Confirm the specific definitions of "cause," "good reason," and "change in control" within the full text of the Severance Plan and Employment Agreement.
- Assess the potential financial impact of accelerated equity vesting on future dilution.
- Review the total potential payout liability for the CEO and other covered executives under various change-in-control scenarios.